Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16894355rdf:typepubmed:Citationlld:pubmed
pubmed-article:16894355lifeskim:mentionsumls-concept:C0225336lld:lifeskim
pubmed-article:16894355lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:16894355lifeskim:mentionsumls-concept:C0007581lld:lifeskim
pubmed-article:16894355lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:16894355lifeskim:mentionsumls-concept:C0332157lld:lifeskim
pubmed-article:16894355lifeskim:mentionsumls-concept:C1948023lld:lifeskim
pubmed-article:16894355lifeskim:mentionsumls-concept:C0549178lld:lifeskim
pubmed-article:16894355lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:16894355lifeskim:mentionsumls-concept:C1292733lld:lifeskim
pubmed-article:16894355pubmed:issue10lld:pubmed
pubmed-article:16894355pubmed:dateCreated2006-9-19lld:pubmed
pubmed-article:16894355pubmed:abstractTextAlthough the antiangiogenic activity of type I interferons (IFN) is well known, the mechanism by which it occurs is unclear. In the present study, we have investigated effects of short-term and long-term IFN-alpha exposure on different types of endothelial cells (EC). Short-term IFN-alpha treatment resulted in a distinct reduction of apoptosis of serum and growth factor starved HUVEC and HDMEC. This was accompanied by a strong upregulation of the IFN inducible guanylate binding protein-1 (GBP-1) whereas no consistent regulation of several known antiapoptotic proteins was evident. Stable transfection of HUVEC with an expression vector for GBP-1 mimicked the protective effect of IFN-alpha, suggesting that GBP-1 may contribute to the inhibition of apoptosis. When IFN-alpha, together with serum and EC growth factors, was present continuously a decrease of population doublings by more than 40% was observed in both HDMEC and HCAEC. In addition, the cells displayed a senescent phenotype significantly earlier than control cells and showed an increased adherence for monocytes. Our findings suggest that the antiangiogenic effect of IFN-alpha is mediated by inducing EC senescence rather than EC apoptosis. Furthermore IFN-alpha released in chronic inflammatory conditions might contribute via its prosenescent activity to the pathogenesis of atherosclerosis.lld:pubmed
pubmed-article:16894355pubmed:languageenglld:pubmed
pubmed-article:16894355pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16894355pubmed:citationSubsetIMlld:pubmed
pubmed-article:16894355pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16894355pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16894355pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16894355pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16894355pubmed:statusMEDLINElld:pubmed
pubmed-article:16894355pubmed:monthOctlld:pubmed
pubmed-article:16894355pubmed:issn0023-6837lld:pubmed
pubmed-article:16894355pubmed:authorpubmed-author:TschachlerErw...lld:pubmed
pubmed-article:16894355pubmed:authorpubmed-author:BirnerPeterPlld:pubmed
pubmed-article:16894355pubmed:authorpubmed-author:PammerJohanne...lld:pubmed
pubmed-article:16894355pubmed:authorpubmed-author:ReinischChris...lld:pubmed
pubmed-article:16894355pubmed:authorpubmed-author:PogodaKristin...lld:pubmed
pubmed-article:16894355pubmed:authorpubmed-author:SturzlMichael...lld:pubmed
pubmed-article:16894355pubmed:issnTypePrintlld:pubmed
pubmed-article:16894355pubmed:volume86lld:pubmed
pubmed-article:16894355pubmed:ownerNLMlld:pubmed
pubmed-article:16894355pubmed:authorsCompleteYlld:pubmed
pubmed-article:16894355pubmed:pagination997-1007lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:meshHeadingpubmed-meshheading:16894355...lld:pubmed
pubmed-article:16894355pubmed:year2006lld:pubmed
pubmed-article:16894355pubmed:articleTitleInterferon-alpha prevents apoptosis of endothelial cells after short-term exposure but induces replicative senescence after continuous stimulation.lld:pubmed
pubmed-article:16894355pubmed:affiliationInstitute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.lld:pubmed
pubmed-article:16894355pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16894355pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:3397entrezgene:pubmedpubmed-article:16894355lld:entrezgene
entrez-gene:2633entrezgene:pubmedpubmed-article:16894355lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:16894355lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:16894355lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16894355lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16894355lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16894355lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16894355lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16894355lld:pubmed